文献速递湿疹皮炎与荨麻疹

特应性皮炎的医疗质量评估——一套质量指标的制定与应用

Measurement of healthcare quality in atopic dermatitis - development and application of a set of quality indicators.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-06-13

由德国特应性皮炎指南组10名专家通过德尔菲法制定5项结局质量和12项过程质量指标,并回顾性应用于一项纳入1678例特应性皮炎患者的全国性研究。过程质量总指数中位数为62.5,与SCORAD(rp=0.08)、DLQI(rp=0.256)和PBI(rp=-0.151)等结局质量指标不相关或仅轻微相关。结论认为特应性皮炎的过程质量中等至良好,但过程质量指数与患者健康状况无实质相关性,需进一步研究指标的信度、反应度和可行性。

要点

  • 专家委员会通过德尔菲法制定5项结局质量和12项过程质量指标。
  • 过程质量总指数中位数为62.5(范围0至100)。
  • 过程质量指数与SCORAD、DLQI、PBI等结局指标不相关或仅轻微相关。

核心结论

  • 特应性皮炎的过程质量中等至良好。
  • 过程质量指数与5项结局质量指标测得的患者健康状况无实质相关性。
  • 作者建议进一步研究应包括所提出的特应性皮炎质量指标的信度、反应度和可行性。

研究设计与样本

  • 由德国特应性皮炎指南组的10名成员组成专家委员会,使用德尔菲法将潜在质量指标浓缩为最终5项结局质量指标和12项过程质量指标。
  • 将结局质量指标和7项或8项过程质量指标回顾性应用于一项纳入1678例特应性皮炎患者的全国性研究(AtopicHealth)。
  • 将每项过程质量指标得分相加得出总指数,范围从0(未达到质量)到100(完全达到质量)。

主要发现

  • 过程质量总指数的中位数为62.5。
  • 过程质量总指数与SCORAD中位数的rp=0.08。
  • 过程质量总指数与DLQI的rp=0.256。
  • 过程质量总指数与PBI的rp=-0.151。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者建议进一步研究应包括所提出的特应性皮炎质量指标的信度、反应度和可行性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quality indicators are essential tools for the assessment of health care, in particular for guideline-based procedures. OBJECTIVE: Development of a set of indicators for the evaluation of process and outcomes quality in atopic dermatitis (AD) care. Application of the indicators to a cross-sectional study and creation of a global process quality index. METHODS: An expert committee consisting of 10 members of the German guideline group on AD condensed potential quality indicators to a final set of 5 outcomes quality and 12 process quality indicators using a Delphi panel. The outcomes quality and 7 resp. 8 process quality indicators were retrospectively applied to a nationwide study on 1678 patients with atopic dermatitis (AtopicHealth). Each individual process quality indicator score was then summed up to a global index (ranges from 0 [no quality achieved] to 100 [full quality achieved]) displaying the quality of health care. RESULTS: In total, the global process quality index revealed a median value of 62.5 and did not or only slightly correlate to outcomes quality indicators like the median SCORing Atopic Dermatitis (SCORAD; rp = 0.08), Dermatology Life Quality Index (DLQI; rp = 0.256) and Patient Benefit Index (PBI; rp = -0.151). CONCLUSION: Process quality of AD care is moderate to good. The healthcare process quality index does not substantially correlate to the health status of AD patients measured by 5 different outcomes quality indicators. Further research should include the investigation of reliability, responsiveness and feasibility of the proposed quality indicators for AD.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Steinke S, Beikert FC, Langenbruch A, et al. Measurement of healthcare quality in atopic dermatitis - development and application of a set of quality indicators. J Eur Acad Dermatol Venereol. 2018. PMID: 29763514. doi:10.1111/jdv.15074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。